key: cord-0956724-p6w2gz46
authors: Abobaker, Anis; Darrat, Milad
title: Letter to the Editor from Anis Abobaker: Circulating Levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients
date: 2021-03-23
journal: J Endocr Soc
DOI: 10.1210/jendso/bvab052
sha: 764a9e6967059a3e258d5ce992871fa098d81faa
doc_id: 956724
cord_uid: p6w2gz46

nan

A c c e p t e d M a n u s c r i p t

We read with great interest the research article of Ochea-Callejero L et al who detected low circulatory levels of calcitonin gene-related peptide (CGRP) in patients with COVID-19 regardless of disease severity [1] . CGRP is a peptide molecule which has a role in some aspects of pulmonary physiology, such as pulmonary vasoregulation and tissue repair [1] . Ochea-Callejero L et al suggested that restoration of normal CGRP circulatory levels can be considered as a potential therapeutic option in COVID-19 [1] . They supported their argument with the fact that low levels of CGRP could have a negative impact on lung physiology as it increases risk of vasoconstriction which could lead to pulmonary hypertension, and negatively affects angiogenesis and epithelial repair [1, 2] . In addition, Ochea-Callejero L et al found an increased expression of CGRP receptors in proliferating type II pneumocytes of three patients died of COVID-19 as compared with non-COVID-19 patients [1] . This might indicate that CGRP has an important role in lung epithelial repair process following viral induced acute lung injury. Despite the findings of this study, we think that restoring the normal circulatory levels of CGRP in patients with COVID-19 could potentially cause harmful effects. There are multiple evidence in the literature suggest that during acute infectious or inflammatory stage, CGRP could increase the chance of development of acute lung injury which subsequently leads to adult respiratory distress syndrome (ARDS). In fact, CGRP induces release of inflammatory cytokines, including IL-6, which could trigger the development of massive host inflammatory response, known as cytokine storm [2, 3] . Cytokine storm is considered as a major cause of development of ARDS [4] . Furthermore, CGRP contributes to smoke inhalation lung injury as it increases airways hyperaemia and capillary permeability, which leads to transvascular fluid leakage, through its potent vasodilatory effect [5] . Pre-treatment of animal models with CGRP receptors antagonist provided a protective effect against lung damage induced by smoke inhalation [5] . Another animal study showed that disruption of CGRP gene was protective against acid-induced acute lung injury [6] . Therefore, CGRP receptor antagonist is perhaps a safer and more effective option in management of COVID-19 in comparison with CGRP analogue or restoration of normal circulatory levels of CGRP. However, CGRP receptor antagonist should be used on shortterm basis during the management of COVID-19 as long-term use could abolish the protective effect of CGRP on pulmonary vasoregulation, which in turn increases the risk of development of pulmonary hypertension. The FDA has recently approved the use of CGRP receptor antagonist in phase II clinical trial as a treatment option which might reduce lung inflammation in COVID-19 [2] . Once the results of this clinical trial is available, we might have a better idea about whether CGRP receptor antagonists are effective and safe treatment option in

A c c e p t e d M a n u s c r i p t

Circulating Levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients

CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects

Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Role of calcitonin gene-related peptide (CGRP) in ovine burn and smoke inhalation injury

Calcitonin gene-related peptide mediates acid-induced lung injury in mice